85 results about "Neuronal protection" patented technology

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative as well as a pharmaceutical composition, application and a preparation method thereof. The piperidine derivative has the following general formula. The piperidine derivative can be effectively used for treating or preventing multiple sclerosis, and shows an unexpected synergistic effect in an animal model: the piperidine derivative not only can significantly improve neurological function impairment and promote recovery, but also can deeply reduce the levels of key proinflammatory cytokines IFN-gamma and IL-17 at the same time. The invention provides a novel small molecule candidate drug with central permeability, neuroprotection and comprehensive immune regulation functions for treatment of multiple sclerosis.

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

The invention discloses application of ginsenoside Rg5 in preparation of a medicine for treating Alzheimer's disease and an evaluation method, and relates to application of ginsenoside Rg5 in preparation of a medicine for treating Alzheimer's disease. The medicine improves A beta deposition, tau protein phosphorylation and neuron damage by adjusting the intestinal flora structure and metabolite level, and is used for relieving the pathological process of the Alzheimer's disease. The invention has the characteristics of multi-target effect, nerve protection, inflammation resistance and oxidation resistance.

The application discloses a cardiovascular maintenance functional wine based on a composite fermentation process and a preparation method thereof. Through synergistic fermentation of rosewood flavones, five-grain nutrients and rhizoma notopterygii blood-activating components, a cardiovascular maintenance wine with multiple effects of blood pressure regulation, microcirculation improvement, nerve protection and anti-inflammation is developed. Process parameters are optimized and designed to ensure efficient reservation and release of active components, and the cardiovascular maintenance wine is suitable for daily auxiliary conditioning of sub-healthy people and cardiovascular risk groups.

The application discloses a preparation method and application of a conjugate targeting pelvic autonomic nerves, wherein the conjugate is NE-RH formed by coupling of rhein and norepinephrine, the conjugate can realize precise targeting of norepinephrine neurons, improve the accumulation effect of RH in the norepinephrine neurons, and further enhance the nerve protection effect of RH. The conjugate has a molecular weight of less than 1000 Da, can help to penetrate the blood-brain barrier, and can avoid the defects of being easily removed by a mononuclear phagocyte system and having a short half-life. The production process of the conjugate is simple, the chemical coupling reaction is clear, the yield can reach 38%, and the purity of the product is greater than 99%, so that the conjugate is convenient to popularize and use. The conjugate and the preparation method have important significance for the damage repair of pelvic autonomic nerves.

The invention discloses a system for predicting the risk of nerve injury caused by radiotherapy based on deep learning, and belongs to the technical field of medical artificial intelligence and radiotherapy, and the system comprises a neural structure automatic segmentation module, a dose-neural response modeling module, an individualized risk assessment module, a radiotherapy plan optimization module and a closed-loop feedback regulation unit. The system adopts an encoder-decoder deep network to perform high-precision segmentation on nervous tissues, establishes a dose-nerve response quantitative model by fusing dosiomics and radiomics characteristics, and realizes individualized risk assessment based on a multi-factor risk quantitative network. An optimization scheme for balancing tumor control and neuroprotection is generated through Pareto optimal search, collaborative optimization of all the modules is achieved through closed-loop feedback, and decision support is provided for precise radiotherapy.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The invention discloses a colla corii asini in-vivo bioactive component cyclic dipeptide and a discovery method thereof, and belongs to the technical field of bioactive component analysis and application. The method comprises the following steps: establishing a rat donkey-hide gelatin administration model and collecting a sample, performing solid-phase extraction on the sample, performing LC-MS / MS peptidomics analysis and PEAKS database search, screening exogenous oligopeptides based on a feature-based molecular network (FBMN), performing cyclic dipeptide targeted metabonomics identification, and verifying cell viability. According to the method, 29 cyclic dipeptides are produced by metabolism in donkey-hide gelatin, and the cyclic dipeptides containing hydroxyproline (Hyp) can significantly improve the survival rate of HT-22 cells damaged by glutamic acid or hydrogen peroxide induction and have neuroprotective activity.

The invention provides a duodenum ablation system and method combined with three-dimensional reconstruction. The duodenum ablation system combined with three-dimensional reconstruction comprises a main control unit, a three-dimensional reconstruction module, an intelligent ablation planning module, a neurological function surveying and mapping module, an ablation execution device and a real-time monitoring and feedback control module, through an integrated intracavity electrical stimulation surveying and mapping technology, functional evaluation and mapping can be performed on nerve excitability of a target area before ablation, and a'nerve high-risk area 'is visually marked on a three-dimensional mucous membrane model. When the system performs automatic path planning, the areas can be actively avoided, or verified safe energy parameters are adopted in the areas, so that important intestinal nerve functions are protected to the greatest extent, and the risk of nerve injury related complications is reduced from the source. Therefore, the purposes of intelligent navigation, automatic planning, individualized self-adaptive control and functional nerve protection are achieved.

The present invention relates to a composition for protecting nerve cells, comprising a supercritical extract of Cannabis sativa and, more specifically, to a composition for protecting nerve cells, comprising a supercritical extract of Cannabis sativa, thereby exhibiting an antioxidant effect and a nerve cell death inhibitory effect.

Interleukin-34 is a cytokine that is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Recent work has also demonstrated a new and possible therapeutic role for IL-34 as a Foxp3+ Treg-secreted cytokine mediator of transplant tolerance. New mutated IL-34 polypeptides have been generated, which can be used as agonists or antagonists.

The invention relates to application of NADH (nicotinamide adenine dinucleotide) in preparation of drugs for preventing or treating autism, and further provides a liposome nanoparticle oral preparation for preventing or treating autism, the NADH can reduce central nervous system inflammation, and tests prove that the NADH can remarkably reduce neural immune inflammation of autism model rats, and can be used for preventing or treating autism. The method has the advantages that the method is simple and convenient to operate and has neuroprotection and progeny rat behavioral correction capacity, social experiment defects of progeny rats are overcome, the engraving behaviors of the progeny rats are reduced, the influence of autism-related behaviors of the progeny rats is reversed, and a new scheme is provided for prevention or treatment of autism.

The invention belongs to the technical field of pharmaceutical co-crystals, and particularly relates to a synthetic method and application of an amantadine-butylphthalide co-crystal. Butylphthalide reacts to obtain butylphthalide salt or butylphenyltitanic acid, the butylphthalide salt or butylphenyltitanic acid reacts with different substituted amantadine or hydrochloride thereof to synthesize the pharmaceutical co-crystal, and the co-crystal structure can adjust the crystal lattice energy of the pharmaceutical, improve the solubility of the pharmaceutical in water or physiological media, promote the rapid dissolution and absorption of the pharmaceutical in vivo, improve the bioavailability and improve the bioavailability of the pharmaceutical. According to the eutecticum, the problem of solubility of butylphthalide is solved, the formed eutecticum shows certain neuroprotective activity, the biological activity of the eutecticum is remarkably superior to that of a monomer drug, the clinical medication dosage can be reduced while the same treatment effect is achieved, and the eutecticum has certain scientific research value and industrial popularization significance.

The present disclosure relates to highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and biomedical uses thereof. In particular highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate, is provided for enhancing bodily function and treating various disease states. The methods described herein provide for production of a highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate via processes external to the human body and administering effective amounts of highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate to human subjects to achieve a range of therapeutic benefits, including but not limited to, one or more of: inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additionally, highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate is administered in an amount and frequency conducive to one or more of: improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection. Methods for manufacturing and purifying (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate compositions to ensure high specificity and efficacy in therapeutic applications are also provided.

The invention discloses a spinal stenosis minimally invasive nerve protection decompression device, and relates to the related field of spinal stenosis minimally invasive, the spinal stenosis minimally invasive nerve protection decompression device comprises a fixing cylinder, the outer side of the upper end of the fixing cylinder is fixedly provided with a connecting block, and the lower end of the circle center of the fixing cylinder is movably provided with a fixing long needle; the top of the fixed long needle is fixed to the bottom end of the rotating ball body, a locking mechanism is arranged at the bottom of the threaded pipe, and the locking mechanism acts between the rotating ball body and the fixed ball body to achieve relative locking of the rotating ball body and the fixed ball body. According to the spinal canal stenosis minimally invasive nerve protection decompression equipment, a second rotating block drives a threaded pipe to move downwards, an arc-shaped ball is driven to extrude two sets of symmetrical locking blocks, the position of a drag hook can be accurately controlled, and the complexity and injury risk of manual nerve traction are avoided; through the cooperation of the penetrating type cleaning pipe and the one-way nozzle, the operation area can be cleaned synchronously, the pollution hidden danger in the operation is reduced, and the multiple requirements for nerve protection, operation efficiency and operation precision in the minimally invasive scene are met on the whole.

An adhesive ulnar nerve protection device for protecting the ulnar nerve of a patient comprises a foam member and a first releasably-adhesive component. The foam member comprises a first side and a second side, and is sized and shaped to accommodate substantially the entire ulnar nerve region of a patient's arm. The first releasably-adhesive component is disposed upon the first side of the device, and the first side of the device is disposed around and adhesively attached to substantially the entire ulnar nerve region of the patient's arm during use. In some embodiments, the adhesive ulnar nerve protection device further comprises a second releasably-adhesive component disposed upon the second side of the device. In such embodiments, the second side of the device can be disposed upon and adhesively attached to a medical furnishing and / or another portion of the patient's body during use.

MicroRNA modified umbilical cord mesenchymal stem cells and exosomes and applications. The present application provides a treatment technology based on miR-210 mutant umbilical cord mesenchymal stem cells and exosomes. By specifically modifying the miR-210 sequence, a mutant with enhanced stability and targeting efficiency is obtained. After being introduced into umbilical cord mesenchymal stem cells, exosomes with high expression of the mutant can be prepared. The exosomes show significant therapeutic effect in various disease models, including promoting angiogenesis, accelerating wound repair and neuroprotection. The present application simultaneously protects the mutant sequence, recombinant vector, recombinant cell and its preparation method, and the application of the exosomes in the preparation of drugs for treating ischemic diseases and tissue damage. This technology optimizes the sequence and delivery system of miR-210, providing a new solution for tissue repair.

The invention discloses application of salvianolic acid C in preparation of a medicine for preventing and / or treating retinal ischemia hypoxic nerve injury diseases, and relates to the technical field of biological medicines. The invention proposes and verifies for the first time that salvianolic acid C can significantly promote the formation of stress particles in photoreceptor cells under retinal ischemia and hypoxia conditions, and drives the salvianolic acid C to be assembled into a stress particle-mitochondrial micro-region in a mitochondrial adjacent region. The microcell is enriched in DDX3X, LARP1 and other key RNA binding proteins and multiple mitochondrial related proteins to cooperatively maintain mitochondrial membrane potential, inhibit mPTP opening and reduce ROS generation, so that an endogenous apoptosis pathway is inhibited, and the neuroprotective effect on a photoreceptor is achieved. On the basis, the salvianolic acid C is used for preparing the medicine for preventing and / or treating the retinal ischemia hypoxia nerve injury disease, can be used as a nerve protection supplement for existing anti-VEGF treatment, and has innovativeness and application value.

The invention relates to the technical field of bioactive peptides, in particular to application of sipunculus nudus polypeptide in preparation of a neuroprotective drug. According to the specific technical scheme, firstly, sipunculus nudus oligopeptide is obtained through enzymolysis and an ultrafiltration membrane separation technology, the sipunculus nudus oligopeptide is separated and purified through sephadex chromatography, and on the basis of a high-glucose-induced mouse hippocampal neuron HT22 cell damage model, the collected components are separated and purified to obtain the sipunculus nudus oligopeptide. The neuroprotective effects of the sipunculus nudus oligopeptide and the separated components thereof are deeply discussed, and then the components in the sipunculus nudus oligopeptide are further separated and purified and subjected to mass spectrum peptide sequence identification by adopting reverse-phase high performance liquid chromatography. Experimental results show that the three components separated from the sipunculus nudus oligopeptide through sephadex chromatography can effectively improve the cell activity of HT22 cells after high glucose damage, and accumulation of ROS (reactive oxygen species) in the cells and occurrence of apoptosis are remarkably reduced.

The invention discloses a method for obtaining enhanced IMD-0354 and application of the enhanced IMD-0354 in neuroprotection, and relates to the technical field of biological medicine. The method comprises the following steps: 1) regulating and controlling the expression or activity of IRF5 in myeloid-derived proinflammatory immune cells, so that the expression quantity of the IRF5 is reduced or the activity of the IRF5 is inhibited; and (2) co-culturing the IRF5 regulation type myeloid-derived proinflammatory immune cells obtained in the step (1) and nerve cells in a neurodegenerative disease cell model related to TDP-43 pathology in a culture system containing IMD-0354 so as to enhance the protection effect of the IMD-0354 on the nerve cells. The application disclosed by the invention has the beneficial effects that the neuroprotection of the IMD-0354 on ALS cells is enhanced, the interference of proinflammatory macrophages on the IMD-0354 is antagonized, and a thought is provided for ALS treatment and drug research and development.

This invention belongs to the field of biomedical technology and relates to the application of PAX8 gene inhibitors in the preparation of drugs for treating optic nerve degeneration. The PAX8 gene inhibitor is a shRNA that targets and inhibits the PAX8 gene or a vector expressing a shRNA that targets and inhibits the PAX8 gene. The vector uses the astrocyte-specific promoter gfabc1d. Experiments have demonstrated that by specifically inhibiting PAX8 expression in astrocytes, axoplasmic transport obstruction in the optic nerve is relieved, optic nerve degeneration is alleviated, and a new gene therapy strategy is provided for the protective treatment of optic nerve degeneration in glaucoma.

The present application provides a composition, a compound, a wolfberry agmatine enriched part and its neuroprotective use. The wolfberry agmatine enriched part extracted from wolfberry fruit has excellent neurocyte protection effect and prevention and treatment effect on Parkinson's disease. The wolfberry agmatine enriched part has simple extraction process and excellent effect, and its neuroprotective effect is not only superior to wolfberry fruit water extract and wolfberry polysaccharide enriched part, but also superior to each wolfberry agmatine monomer.

The invention discloses a derivative with a benzo-nitrogen heterocyclic structure and application thereof, and relates to the technical field of new drug development, and the structure of the derivative is shown as a general formula (I). The compound can inhibit beta-amyloid protein aggregation and acetylcholin esterase activity at the same time, also has excellent antioxidant and neuroprotective effects, and is mainly used for treating and preventing Alzheimer's disease and other nervous system diseases. (I).

The application discloses a preparation method of adamantane nitroketone derivatives and application of the adamantane nitroketone derivatives in ischemic stroke drugs. The adamantane nitroketone derivatives are combined by 2,3,5,6-tetramethylpyrazine and adamantane compounds through nitroketone. The compound not only has strong free radical scavenging capacity, but also integrates the nerve protection function of the adamantane compound.

The invention discloses fructus alpiniae oxyphyllae-derived extracellular vesicle-like nanoparticles as well as a preparation method and application thereof. The preparation method comprises the following steps: soaking a fructus alpiniae oxyphyllae raw material, breaking walls, crushing, centrifugally filtering, concentrating by tangential flow, centrifuging in multiple stages, filtering and the like. According to the preparation method provided by the invention, differential centrifugation is combined with a tangential flow concentration technology, so that the extracellular vesicle-like nanoparticles can be efficiently and completely enriched and purified from the fructus alpiniae oxyphyllae. The whole process is carried out at low temperature, so that the biological activity of the vesicles is protected to the greatest extent, the use of an organic solvent is avoided, and the naturalness and safety of the product are ensured. According to the fructus alpiniae oxyphyllae-derived nanoparticles, by activating IRS-1, promoting PI3K activation, increasing PIP3 generation and activating Akt, GSK-3beta is subjected to phosphorylation to inactivate GSK-3beta, excessive phosphorylation and accumulation of Tau protein are reduced, and plaque formation is delayed. In a diabetic cognitive impairment model, the nanoparticles have a remarkable neuroprotective effect and can improve the cognitive function and reduce inflammatory response.

The present invention relates to a process for obtaining a biocompatible neuroprotective conduit with controlled release of bioactive molecules for nerve regeneration, comprising the steps of: 3D printing an NGC and guide tube from PCL biomaterial; sterilising the NGC; preparing GelMA functionalised with the growth factor FGF-2; inserting the guide tube into the NGC; applying GelMA functionalised with the growth factor FGF-2; photocrosslinking with a UV light head; and removing the guide tube. Furthermore, the present invention also relates to a biocompatible neuroprotective conduit with controlled release of bioactive molecules for nerve regeneration and to uses thereof.